Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 10 07 2018
accepted: 30 11 2018
revised: 14 11 2018
pubmed: 13 1 2019
medline: 19 11 2019
entrez: 13 1 2019
Statut: ppublish

Résumé

To assess if tumour grading based on dynamic [18F]FET positron emission tomography/magnetic resonance imaging (PET/MRI) studies is affected by different MRI-based attenuation correction (AC) methods. Twenty-four patients with suspected brain tumours underwent dynamic [18F]FET-PET/MRI examinations and subsequent low-dose computed tomography (CT) scans of the head. The dynamic PET data was reconstructed using the following AC methods: standard Dixon-based AC and ultra-short echo time MRI-based AC (MR-AC) and a model-based AC approach. All data were reconstructed also using CT-based AC (reference). For all lesions and reconstructions, time-activity curves (TACs) and time to peak (TTP) were extracted using different region-of-interest (ROI) and volume-of-interest (VOI) definitions. According to the most common evaluation approaches, TACs were categorised into two or three distinct curve patterns. Changes in TTP and TAC patterns compared to PET using CT-based AC were reported. In the majority of cases, TAC patterns did not change. However, TAC pattern changes as well as changes in TTP were observed in up to 8% and 17% of the cases when using different MR-AC methods and ROI/VOI definitions, respectively. However, these changes in TTP and TAC pattern were attributed to different delineations of the ROIs/VOIs in PET corrected with different AC methods. PET/MRI using different MR-AC methods can be used for the assessment of TAC patterns in dynamic [18F]FET studies, as long as a meaningful delineation of the area of interest within the tumour is ensured. • PET/MRI using different MR-AC methods can be used for dynamic [18F]FET studies. • A meaningful segmentation of the area of interest needs to be ensured, mandating a visual validation of the delineation by an experienced reader.

Identifiants

pubmed: 30635757
doi: 10.1007/s00330-018-5942-9
pii: 10.1007/s00330-018-5942-9
pmc: PMC6610265
doi:

Substances chimiques

Fluorine Radioisotopes 0
Fluorine-18 GZ5I74KB8G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4276-4285

Subventions

Organisme : Siemens
ID : NA

Références

J Nucl Med. 2006 Mar;47(3):393-403
pubmed: 16513607
Med Phys. 2006 Apr;33(4):976-83
pubmed: 16696474
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42
pubmed: 17763848
J Magn Reson Imaging. 2008 Sep;28(3):543-58
pubmed: 18777528
J Nucl Med. 2009 Apr;50(4):520-6
pubmed: 19289430
Neuro Oncol. 2011 Mar;13(3):307-16
pubmed: 21292686
J Nucl Med. 2012 Feb;53(2):207-14
pubmed: 22302961
Strahlenther Onkol. 2012 Apr;188(4):334-9
pubmed: 22349712
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1021-9
pubmed: 22491781
J Nucl Med. 2012 Jul;53(7):1048-57
pubmed: 22645298
J Nucl Med. 2012 Sep;53(9):1367-74
pubmed: 22872742
Neuro Oncol. 2012 Dec;14(12):1473-80
pubmed: 23090986
MAGMA. 2013 Feb;26(1):99-113
pubmed: 23179594
Neuro Oncol. 2013 Mar;15(3):341-51
pubmed: 23335162
Mol Imaging. 2013 May;12(3):137-47
pubmed: 23490440
Radiother Oncol. 2013 Dec;109(3):487-92
pubmed: 23953407
Neuroimage. 2014 Jan 1;84:206-16
pubmed: 23994317
J Nucl Med. 2013 Dec;54(12):2046-54
pubmed: 24159047
Childs Nerv Syst. 2015 Feb;31(2):261-7
pubmed: 25231277
Neuro Oncol. 2014 Oct;16 Suppl 7:vii12-23
pubmed: 25313234
Cancer Imaging. 2014 Jun 25;14:25
pubmed: 25608761
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1439-46
pubmed: 25900276
Neuro Oncol. 2015 Sep;17(9):1293-300
pubmed: 26008606
J Nucl Med. 2015 Jul;56(7):1061-6
pubmed: 26025957
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):103-112
pubmed: 26363903
Neuro Oncol. 2016 May;18(5):744-51
pubmed: 26578622
J Nucl Med. 2016 Jun;57(6):918-24
pubmed: 26837338
Clin Nucl Med. 2016 May;41(5):e228-36
pubmed: 26859208
J Nucl Med. 2016 Jul;57(7):1096-101
pubmed: 26917707
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Neuroimage. 2017 Feb 15;147:346-359
pubmed: 27988322
J Nucl Med. 2017 Sep;58(9):1519-1525
pubmed: 28254872
Expert Rev Anticancer Ther. 2017 May;17(5):395-397
pubmed: 28277832
J Neurooncol. 2017 Aug;134(1):177-188
pubmed: 28547590
Clin Transl Imaging. 2017;5(2):135-149
pubmed: 28936429
Neuro Oncol. 2018 Jun 18;20(7):907-916
pubmed: 29126125
Sci Rep. 2018 May 8;8(1):7201
pubmed: 29740097

Auteurs

Ivo Rausch (I)

QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.

Andreas Zitterl (A)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Neydher Berroterán-Infante (N)

QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.

Lucas Rischka (L)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Daniela Prayer (D)

Division of Neuroradiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.

Matthias Fenchel (M)

Magnetic Resonance, Siemens Healthcare GmbH, Erlangen, Germany.

Reza A Sareshgi (RA)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Division of Radiology-Technique, University of Applied Science, Vienna, Austria.

Alexander R Haug (AR)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Marcus Hacker (M)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Thomas Beyer (T)

QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.

Tatjana Traub-Weidinger (T)

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. tatjana.traub-weidinger@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH